FDA Approves New Heart Failure Drug

Entresto tablets have been approved for the treatment of heart failure.

The U.S. Food and Drug Administration has approved Entresto tablets for the treatment of heart failure. The drug has been shown to reduce the rate of cardiovascular death and hospitalization related to heart failure, according to the agency.

"Heart failure is a leading cause of death and disability in adults," said Dr. Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Products in FDA's Center for Drug Evaluation and Research. "Treatment can help people with heart failure live longer and enjoy more active lives.

FDA reported the most common side effects in clinical trial participants being treated with Entresto were low blood pressure, high blood potassium levels, and poor kidney function. Entresto is manufactured by Novartis, based in East Hanover, N.J.

Product Showcase

  • SlateSafety BAND V2

    SlateSafety BAND V2

    SlateSafety's BAND V2 is the most rugged, easy-to-use connected safety wearable to help keep your workforce safe and help prevent heat stress. Worn on the upper arm, this smart PPE device works in tandem with the SlateSafety V2 system and the optional BEACON V2 environmental monitor. It includes comprehensive, enterprise-grade software that provides configurable alert thresholds, real-time alerts, data, and insights into your safety program's performance all while ensuring your data is secure and protected. Try it free for 30 days. 3

Featured

Webinars